Research map: Pre-Existing Peak-Dose Dyskinesia and Light Body Weight as Predictors of Ropinirole Patch Dose Modification in Parkinson Disease: A Multicenter Retrospective Study

Back to the article

Papers in this map

  1. Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics · Yoshinobu Kanda · 2012 · 19329 citations · Cited by this paper
  2. Viceroys in the Garden With the Monarch Butterflies: Medical Mimics of Catatonia · 2025 · Related
  3. Gender differences in drug responses · Flavia Franconi · 2006 · 458 citations · Cited by this paper
  4. Impact of Levetiracetam Cost on Epilepsy in a Resource-limited Country · 2025 · Related
  5. Levodopa‐induced dyskinesia in Parkinson disease: Current and evolving concepts · Alberto J. Espay · 2018 · 346 citations · Cited by this paper
  6. Psilocybin Use in the Autism Spectrum Disorder: A Scoping Review · 2025 · Related
  7. Steady-State Plasma Concentration Profile of Transdermal Rotigotine: An Integrated Analysis of Three, Open-Label, Randomized, Phase I Multiple Dose Studies · Jan‐Peer Elshoff · 2012 · 109 citations · Cited by this paper
  8. Amantadine Reduces Adverse Cardiovascular Outcomes in Patients With Parkinsonism or Parkinson Disease: A Global Propensity Score Matched Analysis · 2025 · Related
  9. Continuous Dopaminergic Stimulation as a Treatment for Parkinson's Disease: Current Status and Future Opportunities · C. Warren Olanow · 2020 · 94 citations · Cited by this paper
  10. A Case of Post–Acute Severe Acute Respiratory Syndrome Coronavirus 2–Induced Focal Nonconvulsive Status Epilepticus With Impairment of Consciousness Initially Diagnosed as Anxiety · 2025 · Related
  11. Transdermal drug pharmacokinetics in man: Interindividual variability and partial prediction · Sara Farahmand · 2008 · 62 citations · Cited by this paper
  12. The Impact of Age and Severity of Attention Deficit Hyperactivity Disorder (ADHD) Before COVID-19 on the Severity of ADHD During the COVID-19 Lockdowns, as Reported by the Mothers · 2025 · Related
  13. Comparative effectiveness of dopamine agonists and monoamine oxidase type-B inhibitors for Parkinson’s disease: a multiple treatment comparison meta-analysis · Caroline D. Binde · 2020 · 62 citations · Cited by this paper
  14. Electroconvulsive Therapy for Refractory Anxiety and Depression in Superficial Siderosis: A Case Report · 2025 · Related
  15. Clinical pharmacokinetics of pramipexole, ropinirole and rotigotine in patients with Parkinson's disease · Manuela Contin · 2018 · 33 citations · Cited by this paper
  16. A Double-blind, Placebo-controlled Study of Lumateperone in the Treatment of Borderline Personality Disorder · 2026 · Related
  17. Pharmacokinetics, Safety and Tolerability of Rotigotine Transdermal Patch in Healthy Japanese and Caucasian Subjects · Willi Cawello · 2013 · 32 citations · Cited by this paper
  18. Which is More Important to Enhance or Deteriorate Cognitive Functions in Older Adults With Major Cognitive Impairment: The Drug Burden Index or the Total Number of Medications? · 2025 · Related
  19. Female, aging, difference formulations of DCI, or lower body weight increases AUC4hr of levodopa in patients with Parkinson's disease · Noriko Nishikawa · 2020 · 25 citations · Cited by this paper
  20. Sulforaphane Adjunct to Methylphenidate for Attention-deficit/Hyperactivity Disorder: A Randomized, Double-blind, Placebo-controlled Trial · 2025 · Related
  21. Ropinirole Patch Versus Placebo, Ropinirole Extended‐Release Tablet in Advanced Parkinson's Disease · Nobutaka Hattori · 2020 · 23 citations · Cited by this paper
  22. Regional Subcutaneous Fat Characteristics Stratified by Sex, Age, and Obesity, and Their Relationships with Total and Visceral Fat in a Japanese Population · Susumu Satô · 2009 · 19 citations · Cited by this paper
  23. Long-term study of ropinirole patch in Parkinson's disease patients with/without basal l-dopa · Hideki Mochizuki · 2021 · 9 citations · Cited by this paper
  24. Development of a Physiologically-Based Pharmacokinetic Model for Quantitative Interpretation of Transdermal Drug Delivery of Rotigotine, a Dopamine Agonist for Treating Parkinson’s Disease · Ji-Hun Jang · 2025 · 5 citations · Cited by this paper

Source: OpenAlex (CC0)